Public company snapshots and catalyst previews organized by sector.
| Ticker | Company | Lead Asset | Indication | Stage | Next Catalyst |
|---|---|---|---|---|---|
| MTVA | MetaVia Inc | DA-1726 | Obesity | Phase 1 | 2026-11-09 |
| BCDA | BioCardia Inc | Autologous cell therapy | Heart Failure, Systolic | Phase 3 | 2026-12 |
| CDIO | Cardio Diagnostics Holdings Inc | n/a | n/a | n/a | n/a |
| CYCN | Cyclerion Therapeutics Inc | IW-1973 | Diabetes Mellitus, Type 2 | Hypertension | Phase 2 | n/a |
| Company | Ticker | Catalyst | Timing | Asset | Confidence |
|---|---|---|---|---|---|
| MetaVia Inc | MTVA | Clinical Trial Completion | 2026-11-09 | DA-1726 | Low |
| Skye Bioscience Inc | SKYE | Clinical Trial Completion | 2026-11-20 | Nimacimab injection | Low |
| BioCardia Inc | BCDA | Clinical Trial Completion | 2026-12 | CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) | Low |
| Creative Medical Technology Holdings Inc | CELZ | Clinical Trial Completion | 2027-01-31 | CELZ-201 Administration | Low |
| BioCardia Inc | BCDA | Corporate Update | Q4 2026 | n/a | Low |
| Veru Inc | VERU | Fda Meeting | September 2025 | GLP-1 | Low |